Incretin-Based Therapies: A Paradigm Shift in Blood Pressure Management?
- 1 July 2025
- journal article
- review article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 82 (7) , 1167-1174
Abstract
In the management of hypertension, only limited advances have been made over the past decades. Recent studies highlight the potential of next-generation incretin-based therapeutics, such as GLP-1 RAs (glucagon-like peptide-1 receptor agonists) like semaglutide and dual GLP-1/GIP (glucose-dependent insulinotropic polypeptide) receptor agonists like tirzepatide. These drugs not only promote weight loss but also substantially lower blood pressure (BP) and reduce cardiovascular end points. The extent to which incretin-based therapies improve disease outcomes via weight loss versus so-called direct tissue effects is the subject of great interest, not only for BP but also for other clinical outcomes. Although, incretin-based therapeutics were initially not designed to treat hypertension, clinical studies demonstrate an impressive reduction in BP in patients treated with these agents, with an even more pronounced effect in patients with obesity and hypertension. The current hypertension guidelines must address the robust evidence supporting the use of incretin-based therapeutics in patients with hypertension. A caveat is that no trial to date has used BP reduction as the primary end point when investigating the interaction between GLP-1 or GLP-1/GIP receptor agonists and antihypertensive medications. However, in patients with type 2 diabetes or a body mass index >27 kg/m 2 , these drugs are widely used and lower BP. Taken together, incretin-based therapeutics represent a promising therapeutic tool to improve both BP and cardiovascular outcomes and help evolve the landscape of hypertension treatment.Keywords
This publication has 45 references indexed in Scilit:
- Semaglutide cuts kidney risk in obesityJournal of Endocrinological Investigation, 2024
- The blood pressure lowering effects of glucagon-like peptide-1 receptor agonists: A mini-review of the potential mechanismsCurrent Opinion in Pharmacology, 2023
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or ObesityJAMA, 2021
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or ObesityJAMA, 2021
- Glucagon-like peptide 1 treatment reverses vascular remodelling by downregulating matrix metalloproteinase 1 expression through inhibition of the ERK1/2/NF-κB signalling pathwayMolecular and Cellular Endocrinology, 2020
- A New Look At the Mosaic Theory of HypertensionCanadian Journal of Cardiology, 2020
- Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular diseasePeptides, 2020
- Dulaglutide inhibits high glucose- induced endothelial dysfunction and NLRP3 inflammasome activationArchives of Biochemistry and Biophysics, 2019
- Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trialThe Lancet, 2018
- Direct effects of glucose, insulin, GLP-1, and GIP on bulbospinal neurons in the rostral ventrolateral medulla in neonatal wistar ratsNeuroscience, 2017